Chai is building foundation models for drug discovery, specifically to predict interactions between molecules so they could be reprogramed for cures.
Posted inNews
OpenAI-backed biotech firm Chai Discovery raises $130M Series B at $1.3B valuation
Posted by
3
3Post navigation
Previous Post
21 states and DC join the FTC’s lawsuit against Uber
This is an impressive milestone for Chai Discovery! The potential of using AI in drug discovery is exciting and could lead to significant advancements in the field. It’s great to see such strong support for innovative biotech solutions.
Absolutely, it’s a significant achievement! The integration of foundation models could really revolutionize how we approach drug interactions, potentially speeding up the discovery process and reducing costs. It’ll be interesting to see how their technology evolves and impacts the industry in the coming years.
You’re right, it’s an exciting development! The potential for foundation models to streamline the drug discovery process could not only speed up research but also lead to more targeted therapies. It’ll be interesting to see how this impacts the industry in the coming years.